January 22, 2007: Study Links Antidepressants to Bone Fractures in Older Patients

A recent study learns that the use of some antidepressants by older patients subject them to probable risks of fractures of the bones. The study was conducted by a group of Canadian research scientists and recommends that patients of more than 50 years who are taking the selective serotonin reuptake inhibitors or SSRIs every day, such as Fluvoxamine, Celexa, Prozac, Paxil, and Zoloft will tend to suffer bone fractures.

December 5, 2006: FDA to Review Suicide Risk for Young Adults Taking Antidepressants

The US Food and Drug Administration has announced about the December 13 meeting of those outside the medical community who will consider a new data on the higher risks of suicidality, a medical condition which is characterized by suicidal thinking and behavior among young adults taking antidepressants. This meeting is a follow to earlier two meetings about antidepressants and suicidality in pediatric patients which were conducted last February and September 2004. FDA said that the meetings aimed at modifying antidepressant drug labels which were based on the findings of the panel.

July 2006: Combined Use of Fluvoxamine and Migraine Medicines Risky

US Food and Drug Administration or FDA, released a public health advisory about the use of fluvoxamine and other antidepressants. FDA stated that there were probable risks linked with the combined use of selective serotonin reuptake inhibitors or SSRIs, such as Fluvoxamine, and triptans for migraine headaches. Combined use of these medications may result to a life-threatening condition known as serotonin syndrome.

July 2006: Treatment Challenges of Depression in Pregnancy

FDA released a public health advisory regarding the probable risks of using fluvoxamine and other antidepressants during pregnancy period of mothers of babies born with a severe condition known as persistent pulmonary hypertension of the newborn or PPHN. Babies who were born with PPHN experience abnormal blood flow through the heart and lungs, and therefore, could not get sufficient oxygen to their bodies.

June 30, 2005: Suicidality in Adults Being Treated with Antidepressant Medications

A public health advisory was released by the US Food and Drug Administration or US FDA declaring that there were several latest scientific publications suggested the probability of risks for suicidal behavior among adults who were treated with antidepressants such as fluvoxamine. FDA emphasized that adults who were taking antidepressants for depression should be monitored closely for worsening depression and greater risk for suicidality. Monitoring these patients were essential when the treatment started and when the dosage were increased or reduced. FDA is working closely with the manufacturers of antidepressants to completely assess the risk of suicidality among adults who were being treated with these medications.

October 15, 2004: FDA Orders Re-Labeling on Suicidality in Child and Adolescent Antidepressant Patients

FDA directed all antidepressant drug manufacturers through a public health advisory, to modify their product labeling to place a boxed warning and expanded warning statements to inform healthcare providers to high potential risks of suicidality, a condition characterized by suicidal thinking and behavior, among children and adolescents who were being treated with these medications.